Drug Interactions between ospemifene and Tivicay PD
This report displays the potential drug interactions for the following 2 drugs:
- ospemifene
- Tivicay PD (dolutegravir)
Interactions between your drugs
No interactions were found between ospemifene and Tivicay PD. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
ospemifene
A total of 97 drugs are known to interact with ospemifene.
- Ospemifene is in the drug class selective estrogen receptor modulators.
- Ospemifene is used to treat the following conditions:
Tivicay PD
A total of 195 drugs are known to interact with Tivicay PD.
- Tivicay pd is in the drug class integrase strand transfer inhibitor.
- Tivicay pd is used to treat HIV Infection.
Drug and food interactions
ospemifene food
Applies to: ospemifene
ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of ospemifene. In a cross-study comparison, administration of a single 60 mg dose of ospemifene with a high-fat/high-calorie meal (860 kcal) in postmenopausal women increased ospemifene peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.3- and 1.7-fold, respectively, compared to administration under fasted condition. Elimination half-life and time to maximum concentration (Tmax) were not altered. In two separate food effect studies where different ospemifene tablet formulations were given to healthy male volunteers, ospemifene Cmax and AUC increased by 2.3- and 1.8-fold, respectively, with a low-fat/low-calorie meal (300 kcal) and 3.6- and 2.7-fold, respectively, with a high-fat/high-calorie meal (860 kcal) relative to fasting.
MANAGEMENT: Ospemifene should be taken once daily with food.
References (1)
- (2013) "Product Information. Osphena (ospemifene)." Shionogi USA Inc
dolutegravir food
Applies to: Tivicay PD (dolutegravir)
Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.
References (1)
- (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.